Published in Women's Health Weekly, April 14th, 2005
According to published research from the United States, "antigen-targeted immunotherapy is an emerging treatment for breast cancer. However, useful breast cancer antigens are only found in a subset of cancer patients. BA46, also known as lactadherin, is a membrane-associated glycoprotein that is expressed in most breast cancer cells but not in general hematopoietic cell populations."
"Moreover, it is much more difficult to generate CTLs against self-antigens," wrote Y. Liu and colleagues, University of Arkansas for Medical Sciences, Department of Obstetrics and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly